The ability of CNTF and its analogs to overcome leptin resistance in mouse models of obesity (Gloaguen et al., 1997; Lambert et al., 2001) and in obese patients (Ettinger et al., 2003) underscores its potential as an anti-obesity drug. Here, CNTF is linked to obesity due to melanocortin 4 receptor deficiency.